TY  - JOUR
AU  - Foskolou, Iosifina P
AU  - Bunse, Lukas
AU  - Van den Bossche, Jan
TI  - 2-hydroxyglutarate rides the cancer-immunity cycle.
JO  - Current opinion in biotechnology
VL  - 83
SN  - 0958-1669
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2023-01536
SP  - 102976
PY  - 2023
AB  - 2-hydroxyglutarate (2HG) is a biproduct of the Krebs cycle, which exists in a D- and L- enantiomer and is structurally similar to α-ketoglutarate. Both 2HG enantiomers have been described to accumulate in diverse cancer and immune cells and can influence cell fate and function. While D-2HG was originally considered as an 'oncometabolite' that aberrantly builds up in certain cancers, it is becoming clear that it also physiologically accumulates in immune cells and regulates immune function. Conversely, L-2HG is considered as an 'immunometabolite' due to its induction and regulatory function in T cells, but it can also be induced in certain cancers. Here, the authors review the effects of both 2HG enantiomers on immune cells within the tumor microenvironment.
LB  - PUB:(DE-HGF)16
C6  - pmid:37515937
DO  - DOI:10.1016/j.copbio.2023.102976
UR  - https://inrepo02.dkfz.de/record/277868
ER  -